GSK : Very good start to the year
>Q1 beat expectations - GSK reported Q1 sales (+4.4% vs consensus) and core EPS (+15.9% vs consensus) ahead of expectations. Sales were up 10% at cc (+6% GBP). All divisions turned in a good performance: Specialty Medicines (+12.8%, +1% vs css), Vaccines (+11.6%, +5.5% vs consensus) driven by Arexvy (£ 180m - launched in Q3 2023, in line) and Shingrix (+13.4%, +4.4% vs consensus) General Medicine declined less sharply than expected (-4.4%, +7.7% vs consensus). Core EB...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.